ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Digital speech-based markers to advance prognosis in Alzheimer's disease.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Validated prognostic tools are essential to advance drug development and clinical care in Alzheimer's disease, particularly as the field shifts toward the prevention of cognitive decline. While progress has been made in developing blood-based biomarkers for the early detection of amyloid pathology, amyloid positivity alone does not reliably predict progression to symptomatic disease. Digital markers can serve as complementary prognostic tools to inform early intervention strategies. Among digital markers, speech-based markers offer a scalable, non-invasive, and cost-effective approach to predicting and monitoring cognitive decline. However, the development of validated speech-based tools has been constrained by the lack of large, multilingual datasets with longitudinal sampling, deep phenotyping, harmonized clinical and biomarker data, and adequate representation of preclinical populations. SpeechDx is a 3-year, multinational, multilingual observational study (n = 2006) designed to address these gaps and accelerate the development of speech-based tools to inform early risk assessment, enable timely intervention, and guide personalized care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.